益盛药业(002566) - 2014 Q3 - 季度财报

Financial Performance - Operating revenue for the current period was CNY 183,996,361.29, reflecting a year-on-year increase of 12.79%[7] - Net profit attributable to shareholders decreased by 21.79% to CNY 18,946,964.14 compared to the same period last year[7] - The net profit attributable to shareholders after deducting non-recurring gains and losses fell by 23.36% to CNY 13,857,966.32[7] - Revenue increased by 10.25% year-on-year, mainly due to increased sales during the period[17] - The company expects a net profit attributable to shareholders of the listed company to range from 87.32 million to 104.78 million yuan, representing a change of 0.00% to 20.00% compared to the previous year[22] Assets and Liabilities - Total assets increased by 12.16% to CNY 2,120,474,744.50 compared to the end of the previous year[7] - Accounts receivable increased by 16.82% compared to the beginning of the period, primarily due to increased sales[16] - Cash and cash equivalents decreased by 27.63% compared to the beginning of the period, primarily due to the procurement of fresh and red ginseng[17] - Accounts receivable decreased by 36.83% compared to the beginning of the period, mainly due to the maturity of bank acceptance bills[17] - Prepayments increased by 190.04% compared to the beginning of the period, primarily due to increased advance payments for red ginseng procurement[17] Cash Flow - Cash flow from operating activities showed a significant increase of 216.91% year-to-date, totaling CNY -209,315,738.30[7] - Cash paid for other operating activities increased by 56.47% year-on-year, attributed to higher sales expenses and market expansion efforts[16] - Cash received from borrowings increased by CNY 260 million year-on-year, mainly due to an increase in short-term borrowings[16] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 19,653[11] - The largest shareholder, Zhang Yisheng, holds 38.88% of the shares, totaling 128,677,572 shares[11] Expenses and Investments - Sales expenses increased by 14.43% year-on-year, primarily due to increased sales and market expansion efforts[17] - Financial expenses increased by 139.00% year-on-year, mainly due to increased interest expenses from short-term borrowings[17] - Investment income increased by 107.16% year-on-year, primarily due to increased returns from financial product investments[17] Future Plans - The company is actively conducting due diligence and assessments related to the acquisition of assets through the issuance of shares and cash payments[18] - The company plans to enhance marketing efforts and expects sales of ginseng-related products to commence in the fourth quarter[22]